BiotechTube

CSL312 + Placebo

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hereditary Angioedema

Conditions

Hereditary Angioedema

Trial Timeline

Jan 27, 2021 → Jun 7, 2022

NCT ID
NCT04656418

About CSL312 + Placebo

CSL312 + Placebo is a phase 3 stage product being developed by CSL for Hereditary Angioedema. The current trial status is completed. This product is registered under clinical trial identifier NCT04656418. Target conditions include Hereditary Angioedema.

What happened to similar drugs?

3 of 20 similar drugs in Hereditary Angioedema were approved

Approved (3) Terminated (0) Active (17)
✅Berinert, lyophilizate for IV application containing 500 IU C1-INH to be reconstituted with 10 mL water for injectionCSLApproved
✅GaradacimabCSLApproved
✅IdebenoneSanthera PharmaceuticalsApproved
🔄KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3
🔄Placebo + KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3
🔄KVD900 150 mg + KVD900 300 mg + KVD900 600 mgKalVista PharmaceuticalsPhase 3
🔄KVD900 600 mg + Drug: KVD900 300 mgKalVista PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT04656418Phase 3Completed
NCT04281524Phase 1/2Withdrawn

Competing Products

20 competing products in Hereditary Angioedema

See all competitors
ProductCompanyStageHype Score
KVD900KalVista PharmaceuticalsPhase 2
29
KVD824 + Placebo to KVD824KalVista PharmaceuticalsPhase 1
23
KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3
38
SebetralstatKalVista PharmaceuticalsPre-clinical
20
KVD900 + Placebo to KVD900KalVista PharmaceuticalsPhase 1
23
SebetralstatKalVista PharmaceuticalsPre-clinical
24
Placebo + KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3
34
KVD824 Prototype 1 modified-release tablet + KVD824 Prototype 2 modified-release tablet + KVD824 Immediate-Release Capsule + Placebo to KVD824 Prototype 1 + KVD824 Prototype 3 modified-release tabletKalVista PharmaceuticalsPhase 1
23
KVD900 150 mg + KVD900 300 mg + KVD900 600 mgKalVista PharmaceuticalsPhase 3
34
KVD824 + Placebo to KVD824KalVista PharmaceuticalsPhase 2
21
KVD900 600 mg + Drug: KVD900 300 mgKalVista PharmaceuticalsPhase 3
38
Deferasirox FCTNovartisPhase 2
27
Canakinumab + PlaceboNovartisPhase 3
40
IlarisNovartisPre-clinical
33
Standard of Care for Haemophilia ARochePre-clinical
26
EmicizumabRochePhase 3
40
TafamidisPfizerPre-clinical
26
tafamidisPfizerPre-clinical
26
NitisinoneSwedish Orphan BiovitrumPre-clinical
26
NitisinoneSwedish Orphan BiovitrumPhase 1
29